United States Antiviral Drug Market Size & Outlook, 2026-2034
United States Antiviral Drug Market Insights
- As highlighted in Packaging Market Insights analysis, the United States Antiviral Drug Market, worth USD 18435.37 Million in 2025, is forecasted to achieve USD 33638.39 Million by 2034.
- The United States market is anticipated to grow at a CAGR of 6.98% during the period 2026–2034.
- By 2025, DNA Polymerase Inhibitors represented the largest share of the Drug Class market size.
- Protease Inhibitors is expected to remain the key growth driver within Drug Class, registering the fastest CAGR during the forecast period.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- United States accounted for 28.72% of the global Antiviral Drug Market size in 2025.
- By 2034, United States is expected to remain the top global market in terms of size.
- Within North America, United States is forecasted to dominate the regional Antiviral Drug Market size by 2034.
- United States will be the fastest-growing market in North America, projected to achieve USD 33835.7 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 18435.37 Million |
| Market Size In 2034 | USD 33638.39 Million |
| Largest segment | DNA Polymerase Inhibitors |
| Units | Revenue in USD Million |
| CAGR | 6.98% (2026-2034) |
| Segmnetation Covered | |
| Drug Class |
|
| Application |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
United States Antiviral Drug Market Drug Class 2026-2034 (USD Million)
| Drug Class | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA Polymerase Inhibitors | XX.x | XX.x | XX.x | 10109.96 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Reverse Transcriptase Inhibitors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Protease Inhibitors | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
United States Antiviral Drug Market Application 2026-2034 (USD Million)
| Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIV | XX.x | XX.x | XX.x | 9319.08 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hepatitis | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Influenza | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.